WO2009097596A1 - Compositions et méthodes pour le traitement d'infections chroniques - Google Patents

Compositions et méthodes pour le traitement d'infections chroniques Download PDF

Info

Publication number
WO2009097596A1
WO2009097596A1 PCT/US2009/032772 US2009032772W WO2009097596A1 WO 2009097596 A1 WO2009097596 A1 WO 2009097596A1 US 2009032772 W US2009032772 W US 2009032772W WO 2009097596 A1 WO2009097596 A1 WO 2009097596A1
Authority
WO
WIPO (PCT)
Prior art keywords
pathogen
antimicrobial
organism
intracellular
acidic
Prior art date
Application number
PCT/US2009/032772
Other languages
English (en)
Inventor
Paul Griffin
Original Assignee
Paul Griffin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul Griffin filed Critical Paul Griffin
Publication of WO2009097596A1 publication Critical patent/WO2009097596A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions et des méthodes pour le traitement et l'élimination d'infections intracellulaires chroniques dans des cellules ou des organismes. Les compositions peuvent comprendre une ou plusieurs substances acides et une ou plusieurs substances antimicrobiennes, administrées en combinaison ou séparément. Les méthodes peuvent consister à administrer une dose d'une ou plusieurs de ces compositions dans une cellule ou un organisme infecté pendant une période allant de plusieurs jours à plusieurs années, jusqu'à ce que l'infection soit sensiblement éliminée.
PCT/US2009/032772 2008-01-31 2009-01-31 Compositions et méthodes pour le traitement d'infections chroniques WO2009097596A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36375508A 2008-01-31 2008-01-31
US2490508P 2008-01-31 2008-01-31
US12/363,755 2008-01-31
US61/024,905 2008-01-31

Publications (1)

Publication Number Publication Date
WO2009097596A1 true WO2009097596A1 (fr) 2009-08-06

Family

ID=40913295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/032772 WO2009097596A1 (fr) 2008-01-31 2009-01-31 Compositions et méthodes pour le traitement d'infections chroniques

Country Status (1)

Country Link
WO (1) WO2009097596A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US20210008011A1 (en) * 2019-07-08 2021-01-14 Charles W. Stratton Methods for treating inflammatory diseases
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11724985B2 (en) 2020-05-19 2023-08-15 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016289A1 (en) * 1995-06-01 2002-02-07 Orla M. Conneely Methods for treatment and prevention of helicobacter pylori infection using lactoferrin
US20020049183A1 (en) * 2000-01-10 2002-04-25 Saul Yedgar Use of lipid conjugates in the treatment of disease
US20040121979A1 (en) * 2001-04-30 2004-06-24 Rudy Susilo Pharmaceutically active uridine esters
US6927227B2 (en) * 1999-04-05 2005-08-09 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US20060003944A1 (en) * 2004-05-21 2006-01-05 Tomasz Glinka Bacterial efflux pump inhibitors and methods of treating bacterial infections
US20070015718A1 (en) * 1997-05-06 2007-01-18 Vanderbilt University Diagnosis and management of infection caused by Chlamydia

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016289A1 (en) * 1995-06-01 2002-02-07 Orla M. Conneely Methods for treatment and prevention of helicobacter pylori infection using lactoferrin
US20070015718A1 (en) * 1997-05-06 2007-01-18 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6927227B2 (en) * 1999-04-05 2005-08-09 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US20020049183A1 (en) * 2000-01-10 2002-04-25 Saul Yedgar Use of lipid conjugates in the treatment of disease
US20040121979A1 (en) * 2001-04-30 2004-06-24 Rudy Susilo Pharmaceutically active uridine esters
US20060003944A1 (en) * 2004-05-21 2006-01-05 Tomasz Glinka Bacterial efflux pump inhibitors and methods of treating bacterial infections

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851451B2 (en) 2017-10-09 2023-12-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11939346B2 (en) 2017-10-09 2024-03-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10947257B2 (en) 2017-10-09 2021-03-16 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10954259B1 (en) 2017-10-09 2021-03-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11149044B2 (en) 2017-10-09 2021-10-19 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11180517B2 (en) 2017-10-09 2021-11-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11447510B2 (en) 2017-10-09 2022-09-20 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11505564B2 (en) 2017-10-09 2022-11-22 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11629159B2 (en) 2017-10-09 2023-04-18 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11738035B2 (en) 2019-04-17 2023-08-29 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US20210008011A1 (en) * 2019-07-08 2021-01-14 Charles W. Stratton Methods for treating inflammatory diseases
US11746088B2 (en) 2020-05-19 2023-09-05 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11834410B2 (en) 2020-05-19 2023-12-05 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11724985B2 (en) 2020-05-19 2023-08-15 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11958807B2 (en) 2020-05-19 2024-04-16 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use

Similar Documents

Publication Publication Date Title
JP6685991B2 (ja) 細菌バイオフィルムの処置および他の使用をはじめとする、生体医学的使用のための消毒薬としてのビスマス−チオール
JP3674873B2 (ja) 非ステロイド系抗−炎症剤および事実上非抗生物性のテトラサイクリンを含む組成物
EP2040724B1 (fr) Compositions biothérapeutiques comprenant du escherichia coli probiotique et de la métronidazole, et leurs utilisations
Do et al. In situ forming implants for periodontitis treatment with improved adhesive properties
Choi et al. Synergistic effect of antimicrobial peptide arenicin-1 in combination with antibiotics against pathogenic bacteria
US20060228384A1 (en) Control of biofilm with a biofilm inhibitor
JPH0780774B2 (ja) 薬剤組成物
Cassidy et al. Development of novel oral formulations prepared via hot melt extrusion for targeted delivery of photosensitizer to the colon
US20180303874A1 (en) Compositions and Methods for the Prevention of Microbial Infections
WO2009097596A1 (fr) Compositions et méthodes pour le traitement d'infections chroniques
US20230355573A1 (en) Antibiotic cannabinoid-terpene formulations
KR20120034626A (ko) 플루오로-퀴놀론을 사용하여 폐의 세균성 감염을 치료하는 방법
US8329663B2 (en) Compositions and methods for the treatment of chronic infections
Batra et al. An in vitro comparison of four antibacterial agents with and without nicotine and their effects on human gingival fibroblasts
CZ2004232A3 (cs) Jednorázová dávka azithromycinu
JP2010538066A5 (fr)
HU215443B (hu) Többféle hatóanyagot tartalmazó gyógyszerkészítmények, főként hüvelykúp, baktericid, fungicid, protozoa- és vírusellenes kombinált hatással
WO2016081825A1 (fr) Procédés et compositions pour le traitement de maladie associée au clostridium difficile
Houri‐Haddad et al. Inflammatory response to chlorhexidine, minocycline HCl and doxycycline HCl in an in vivo mouse model
Maher et al. Melittin as a permeability enhancer II: in vitro investigations in human mucus secreting intestinal monolayers and rat colonic mucosae
TWI482632B (zh) 醫藥用載體及使用該載體的藥物結構
RO120605B1 (ro) Compoziţii farmaceutice cu tizoxanidă şi nitazoxanidă şi utilizarea acestora
US20060073156A1 (en) Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract
Tunalı et al. Apoptosis: an underlying factor for accelerated periodontal disease associated with diabetes in rats
US9283211B1 (en) Oral rapamycin preparation and use for stomatitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09706543

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09706543

Country of ref document: EP

Kind code of ref document: A1